This review provides an overview of recent studies that show the clinical significance of biocompatibility of peritoneal dialysis fluids. 
T here appears to be a certain paradox about the peritoneal dialysis (PD) technique. Peritoneal dialysis fluids (PDF) are infused into the peritoneal cavity in order to generate ultrafiltration across the peritoneum. At the same time, however, long-term PD results in structural alterations in the peritoneal membrane, which make it increasingly difficult to achieve the parameters of dialysis required. Therefore, PD in its present shape may jeopardize the integrity of the organ on which the whole procedure is based. In this review, we analyze results of recent clinical and experimental studies that show the significance of PDF biocompatibility.
Experiments performed by the Aufricht group demonstrated that exposure of human peritoneal mesothelial cells (HPMC) in vitro to conventional PDF resulted in upregulation of heat-shock proteins (1) . These proteins are recruited by cells in response to stress or injury; therefore, their increased expression indicates that PDF cause a great deal of distress to HPMC. In an attempt to determine which factors are responsible for imperfect PDF biocompatibility, Wieslander et al. examined how various PDF components impacted on proliferation of L-929 mouse fibroblasts. These experiments revealed that low pH and glucose degradation products (GDP) accounted for most of the inhibitory effects observed (2) . Indeed, subsequent experiments confirmed that even short-term exposure of HPMC to acidic PDF resulted in a significant loss of cell viability and function (3). Neutralization of the pH markedly alleviated these effects; however, some of the inhibitory potential of PDF persisted. This remaining cytotoxicity was found to depend largely on GDP. Of only a few GDP chemically defined, 3,4-dideoxyglucosone-3-ene (3,4-DGE), formaldehyde, and methylglyoxal were identified as those mainly responsible for adverse effects on HPMC in vitro (4, 5) . The industry promptly answered to the accumulating evidence of PDF bioincompatibility by introducing multicompartment bag systems. This new design allowed minimization of the generation of GDP during heat sterilization of PDF, increase in pH of the solution, and introduction of bicarbonate as a buffering option. New solutions proved to be superior to conventional PDF during in vitro tests; however, their true advantages were to be demonstrated during clinical trials.
In the past 3 years, all new PDF underwent clinical assessment in various study designs ( Table 1 ). The most consistent finding observed in all trials was that of increased concentration of cancer antigen 125 (CA125) in effluent during dialysis with new PDF. In particular, the double crossover Euro Balance Trial demonstrated that dialysate CA125 rose with the introduction of new PDF and fell when patients were switched back to conventional solutions. The clinical significance of increased 
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CA125 is not entirely clear. It has been argued that CA125 levels reflect mesothelial cell mass (12) . Therefore, increased CA125 concentrations may be a sign of better preservation of the peritoneal mesothelium. Interestingly, the effluent drained during dialysis with the new PDF was found to support growth of HPMC better than that obtained from the same patients on conventional PDF (13) . Furthermore, in vitro remesothelialization after scratch wounding occurred without delay in the presence of new PDF but was significantly retarded by standard PDF (4).
The process of mesothelial wound healing appears to be associated with localized synthesis of hyaluronic acid (14) . Thus, the increased presence of hyaluronan may indirectly reflect ongoing tissue regeneration and remodeling after injury. In this respect, several clinical studies observed decreased intraperitoneal levels of hyaluronan during dialysis with new PDF compared with those seen in patients on conventional treatment. A very similar effect was also detected in experimental animals infused with new PDF (15) . In this context, a decrease in intraperitoneal hyaluronan may be interpreted as an indication of reduced irritation of the peritoneal membrane and normalized intraperitoneal homeostasis.
Measurements of other markers in peritoneal drain effluent did not produce unequivocal results. For example, procollagen I peptides (PICP) were reported to either increase (8, 10) or remain unaltered (6) following the switch to the new PDF. Furthermore, it is not clear how increased PICP levels should be interpreted: they may reflect a propensity for fibrosis but may also be viewed as resulting from improved cell function and extracellular matrix turnover.
Irritation of the peritoneum by GDP and the acidity of PDF has long been suspected to cause inflow pain. A recent study showed a significant reduction of subjective pain experienced by patients on automated PD with neutral-pH low-GDP solution (7) . In addition to acute effects, GDP are feared to cause long-term alterations in the peritoneum by inducing glycation of peritoneal proteins. This is because GDP were found to be even more powerful promoters of advanced glycation end-product (AGE) formation than glucose itself. Indeed, formation of AGE in vitro was found to occur much faster in the presence of conventional PDF compared with new low-GDP solutions (16) . In a recent experimental study by Mortier et al., long-term exposure of rats to standard PDF was found to induce peritoneal accumulation of methylglyoxal adducts and AGE and to upregulate the receptor for AGE (RAGE) (17) . Importantly, all these alterations were significantly less pronounced in animals treated with a new PDF. In addition, this group of rats showed decreased expression of vascular endothelial growth factor (VEGF) and nitric oxide synthase, as well as reduced microvascular proliferation and submesothelial fibrosis. Using a model of chronic PDF infusion combined with peritoneal inflammation, Park et al. demonstrated decreased levels of VEGF in dialysate and reduced expression of VEGF in the peritoneum of rats exposed to new PDF (18) . These rats also displayed diminished density (19, 20) . Taken together, these data may suggest there is a link between GDP, AGE, and VEGF that may potentially influence peritoneal permeability. However, this hypothesis remains to be verified since other studies did not produce consistent results. Two recent trials did not record significant changes in VEGF levels during dialysis with low-GDP fluids (10, 11) . Moreover, after the switch to a new solution, an increase in small molecular weight transport and a decrease in peritoneal ultrafiltration were observed (10) . A new animal study by Musi et al.
showed that rats chronically infused with low-GDP solutions displayed increased peritoneal VEGF expression and enhanced vascularization (21) . This effect was interpreted as representing an improvement in peritoneal homeostasis in the absence of GDP-related toxicity. The concentration of GDP in the peritoneum, high immediately after infusion of PDF, decreases with dwell time, probably as a result of absorption into the systemic circulation (9, 22) . This raises the possibility that effects exerted by GDP are not confined to the peritoneal cavity. In this respect, increased levels of circulating AGE were found when patients were dialyzed with conventional PDF compared to when they were receiving low GDP solutions (9) . Furthermore, there was a strong inverse relationship between effluent and plasma levels of AGE and residual renal function (23) .
In summary, long-term exposure to conventional PDF may alter the membrane structure to an extent that leads to increased peritoneal permeability, rapid dissipation of the osmotic gradient, and inadequate dialysis. As the ultrafiltration failure develops, there will be a need to increase the dose of PDF with more hypertonic exchanges. However, this will simultaneously increase glucose and GDP exposure and may exacerbate dysfunction of the peritoneal membrane. There is a growing body of evidence from both in vitro and clinical studies suggesting that adverse effects exerted by PDF can be substantially reduced by eliminating acidity and GDP. This can be achieved in newer multichambered PD solutions.
